Regulus Therapeutics Beta
| RGLSDelisted Stock | USD 8.16 0.01 0.12% |
As of the 18th of February 2026, Regulus Therapeutics holds the Coefficient Of Variation of 483.31, semi deviation of 1.47, and Risk Adjusted Performance of 0.174. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regulus Therapeutics, as well as the relationship between them. Please check Regulus Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Regulus Therapeutics is priced some-what accurately, providing market reflects its current price of 8.16 per share. Given that Regulus Therapeutics has jensen alpha of 3.6, we recommend you to check out Regulus Therapeutics's recent market performance to make sure the company can sustain itself at a future point.
Regulus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Regulus Therapeutics' valuation are provided below:Regulus Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Regulus |
Search Suggestions
| R | Ryder System | Company |
| RF-PC | Regions Financial | Company |
| RCS | Pimco Strategic Income | Fund |
| RB | ProShares Trust | ETF |
| RCI | Dow Jones Composite | Index |
| RSR | RSR | Cryptocurrency |
| R9900CAT3 | YARNO 7378 14 NOV 32 | Corporate Bond |
| RBUSD | Gasoline RBOB | Commodity |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Regulus Therapeutics has a Beta of 0.368. This is 57.21% lower than that of the Biotechnology sector and 73.53% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Regulus Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regulus Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics of similar companies.Regulus Therapeutics is currently under evaluation in beta category among its peers.
As returns on the market increase, Regulus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Regulus Therapeutics is expected to be smaller as well.
Regulus Fundamentals
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | 500.99 M | |||
| Shares Outstanding | 69.23 M | |||
| Shares Owned By Insiders | 2.70 % | |||
| Shares Owned By Institutions | 82.87 % | |||
| Number Of Shares Shorted | 2.09 M | |||
| Price To Earning | (0.69) X | |||
| Price To Book | 8.19 X | |||
| Price To Sales | 7.43 X | |||
| Gross Profit | (36.15 M) | |||
| EBITDA | (45.85 M) | |||
| Net Income | (46.36 M) | |||
| Cash And Equivalents | 47.53 M | |||
| Cash Per Share | 3.25 X | |||
| Total Debt | 274 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 8.82 X | |||
| Book Value Per Share | 1.04 X | |||
| Cash Flow From Operations | (41.67 M) | |||
| Short Ratio | 1.57 X | |||
| Earnings Per Share | (0.68) X | |||
| Price To Earnings To Growth | (0.04) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 34 | |||
| Beta | 0.37 | |||
| Market Capitalization | 564.95 M | |||
| Total Asset | 84.18 M | |||
| Retained Earnings | (559.57 M) | |||
| Working Capital | 74.85 M | |||
| Current Asset | 134.26 M | |||
| Current Liabilities | 12.63 M | |||
| Net Asset | 84.18 M |
About Regulus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regulus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Regulus Stock
If you are still planning to invest in Regulus Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regulus Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |